Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?

Histology and Histopathology

Volumn 24, Issue 2, 2009, Pages 235-242

  Mori, Kanchi ^a   Ando, K ^a   Heymann, D ^b,c,d   Redini F ^b,c  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b INSERM   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d HÔTEL DIEU   (France)

Author keywords

Bone metastasis; Migration; RANK; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; UNCLASSIFIED DRUG;

BONE CANCER; BONE DEFECT; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER CELL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CAUSE OF DEATH; CELL ACTIVITY; CELL GROWTH; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DISEASE COURSE; HUMAN; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BONE; BONE TUMOR; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; METASTASIS; MOUSE; NEOPLASM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE NEOPLASMS; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 59149087622     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D. and Galibert L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
2. Anest V., Hanson J.L., Cogswell P.C., Steinbrecher K.A., Strahl B.D. and Baldwin A.S. (2003). A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423, 659-663.
3. Arguello F., Baggs R.B. and Frantz C.N. (1988). A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 48, 6876-6881.
4. Armstrong A.P., Miller R.E., Jones J.C., Zhang J., Keller E.T. and Dougall W.C. (2008). RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68, 92-104.
5. Arron J.R. and Choi Y. (2000). Bone versus immune system. Nature 408, 535-536.
6. Bakewell S.J., Nestor P., Prasad S., Tomasson M.H., Dowland N., Mehrotra M., Scarborough R., Kanter J., Abe K., Phillips D. and Weilbaecher K.N. (2003). Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc. Natl. Acad. Sci. USA 100, 14205-14210.
7. Bhatia P., Sanders M.M. and Hansen M.F. (2005). Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin. Cancer Res. 11, 162-165.
8. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M. and Vessella R.L. (2001). Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57, 611-616.
9. Bu R., Borysenko C.W., Li Y., Cao L., Sabokbar A. and Blair H.C. (2003). Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 33, 760-770.
10. Canon J.R., Roudier M., Bryant R., Morony S., Stolina M., Kostenuik P.J. and Dougall W.C. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129.
11. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D. and Rabbani S.A. (2006). Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289-298.
12. Coleman R.E. (1997). Skeletal complications of malignancy. Cancer 80, 1588-1594.
13. Corey E., Brown L.G., Kiefer J.A., Quinn J.E., Pitts T.E., Blair J.M. and Vessella R.L. (2005). Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65, 1710-1718.
14. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R. and Penninger J.M. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50.
15. Goltzman D. (2001). Osteolysis and cancer. J. Clin. Invest. 107, 1219-1220.
16. Guise T.A. (2000). Molecular mechanisms of osteolytic bone metastases. Cancer 88, 2892-2898.
17. Herzog C.E. (2005). Overview of sarcomas in the adolescent and young adult population. J. Pediatr. Hematol. Oncol. 27, 215-218.
18. Huang L., Xu J., Wood D.J. and Zheng M.H. (2000). Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am. J. Pathol. 156, 761-767.
19. Jemal A., Siegel R., Ward E., Murray T., Xu J. and Thun M.J. (2007). Cancer statistics, 2007. C.A. Cancer J. Clin. 57, 43-66.
20. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T. and Penninger J.M. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696.
21. Käkönen S.M. and Mundy G.R. (2003). Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97, 834-839.
22. Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O. and Kuramoto A. (1989). Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 73, 2145-2148.
23. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J. and Penninger J.M. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
24. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J. and Boyle W.J. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
25. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D. and Redini F. (2007) Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 67, 7308-7318.
26. Landis S.H., Murray T., Bolden S. and Wingo P.A. (1999). Cancer statistics, 1999. CA. Cancer J. Clin. 49, 8-31.
27. Lin-Lee Y.C., Pham L.V., Tamayo A.T., Fu L., Zhou H.J., Yoshimura L.C., Decker G.L. and Ford R.J. (2006). Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J. Biol. Chem. 281, 18878-18887.
28. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L. and Hung M.C. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3, 802-808.
29. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R. and Grier H. (2005). Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23, 2004-2011.
30. Min W., Bradley J.R., Galbraith J.J., Jones S.J., Ledgerwood E.C. and Pober J.S. (1998). The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity. J. Immunol. 161, 319-324.
31. Miyamoto N., Higuchi Y., Mori K., Ito M., Tsurudome M., Nishio M., Yamada H., Sudo A., Kato K., Uchida A. and Ito Y. (2002). Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int. Immunopharmacol. 2, 25-38.
32. Mori K., Berreur M., Blanchard F., Chevalier C., Guisle-Marsollier I., Masson M., Rédini F. and Heymann D. (2007a). Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol. Rep. 18, 1365-1371.
33. Mori K., Le Goff B., Berreur M., Riet A., Moreau A., Blanchard F., Chevalier C., Guisle-Marsollier I., Léger J., Guicheux J., Masson M., Gouin F., Rédini F. and Heymann D. (2007b). Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J. Pathol. 211, 555-562.
34. Mori K., Le Goff B., Charrier C., Battaglia S., Heymann D. and Rédini F. (2007c). DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40, 981-990.
35. Mountzios G.., Dimopoulos M.A., Bamias A., Papadopoulos G,. Kastritis E., Syrigos K., Pavlakis G.. and Terpos E. (2007). Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46, 221-229.
36. Mundy G.R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593.
37. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T. and Higashio K. (1998). RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253, 395-400.
38. Narita T., Kawakami-Kimura N., Sato M., Matsuura N., Higashiyama S., Taniguchi N. and Kannagi R. (1996). Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Oncology 53, 374-381.
39. Paget S. (1889). The distrubution of secondary growths in cancer of the breast. Lancet 1, 571-572.
40. Peng H., Myers J., Fang X., Stachowiak E.K., Maher P.A., Martins G.G., Popescu G., Berezney R. and Stachowiak M.K. (2002). Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J. Neurochem. 81, 506-524.
41. Rifas L., Arackal S. and Weitzmann M.N. (2003). Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J. Cell Biochem. 88, 650-659.
42. Roodman G.D. (2004). Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664.
43. Sanchez-Sweatman O.H., Lee J., Orr F.W. and Singh G. (1997). Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur. J. Cancer 33, 918-925.
44. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R. and Boyle W.J. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
45. Stiller C.A., Bielack S.S., Jundt G. and Steliarova-Foucher E. (2006). Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42, 2124-2135.
46. Tat S.K., Padrines M., Theoleyre S., Couillaud-Battaglia S., Heymann D., Redini F. and Fortun Y. (2006). OPG/membranous - RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 39, 706-715.
47. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F. and Heymann D. (2004). The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15, 457-475.
48. Whang P.G., Schwarz E.M., Gamradt S.C., Dougall W.C. and Lieberman J.R. (2005). The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J. Orthop. Res. 23, 1475-1483.
49. Wittrant Y., Lamoureux F., Mori K., Riet A., Kamijo A., Heymann D. and Redini F. (2006). RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int. J. Oncol. 28, 261-269.
50. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M. and Choi Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
51. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N. and Suda T. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
52. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J. and Keller E.T. (2001). Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244.
53. Zhang J., Dai J., Yao Z., Lu Y., Dougall W. and Keller E.T. (2003). Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63, 7883-7890.
54. Zhang X.D., Franco A.V., Nguyen T., Gray C.P. and Hersey P. (2000). Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. 164, 3961-3970.